

Addendum

Addendum: Newly diagnosed papillary craniopharyngioma with *BRAF V600E* mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report**Mayank Rao¹, Meenakshi Bhattacharjee², Scott Shepard³ and Sigmund Hsu¹**¹The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA²Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA³Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA**Published:** May 10, 2023**Copyright:** © 2023 Rao et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** Informed patient consent was obtained.Original article: Oncotarget. 2019; 10:6038–6042. <https://doi.org/10.18632/oncotarget.27203>